vs
biote Corp.（BTMD）与Mind Medicine (MindMed) Inc.（DFTX）财务数据对比。点击上方公司名可切换其他公司
biote Corp.的季度营收约是Mind Medicine (MindMed) Inc.的51.2倍（$46.4M vs $906.0K）。biote Corp.净利率更高（4.2% vs -2634.0%，领先2638.2%）。biote Corp.同比增速更快（-6.9% vs -16.1%）
biote Corp是一家专注于个性化生物同质性激素替代疗法的医疗企业，主要面向美国市场运营，为持牌医疗从业者提供相关培训课程，同时推出配套健康补剂与诊断服务，以提升患者诊疗效果。
Definium Therapeutics（前称MindMed）是一家总部位于纽约的生物技术企业，专注于致幻剂及更广泛的精神可塑性药物的临床与治疗应用开发，在中枢神经药物研发领域深耕相关创新疗法的落地潜力。
BTMD vs DFTX — 直观对比
营收规模更大
BTMD
是对方的51.2倍
$906.0K
营收增速更快
BTMD
高出9.2%
-16.1%
净利率更高
BTMD
高出2638.2%
-2634.0%
损益表 — Q4 2025 vs Q4 2023
| 指标 | | |
|---|---|---|
| 营收 | $46.4M | $906.0K |
| 净利润 | $2.0M | $-23.9M |
| 毛利率 | — | — |
| 营业利润率 | 14.7% | -2450.8% |
| 净利率 | 4.2% | -2634.0% |
| 营收同比 | -6.9% | -16.1% |
| 净利润同比 | -47.2% | -386.7% |
| 每股收益（稀释后） | $0.05 | $-0.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BTMDDFTX
| Q4 25 | $46.4M | — | ||
| Q3 25 | $48.0M | — | ||
| Q2 25 | $48.9M | — | ||
| Q1 25 | $49.0M | — | ||
| Q4 24 | $49.8M | — | ||
| Q3 24 | $51.4M | — | ||
| Q2 24 | $49.2M | — | ||
| Q1 24 | $46.8M | — |
净利润BTMDDFTX
| Q4 25 | $2.0M | — | ||
| Q3 25 | $8.2M | — | ||
| Q2 25 | $3.2M | — | ||
| Q1 25 | $13.7M | — | ||
| Q4 24 | $3.7M | — | ||
| Q3 24 | $10.7M | — | ||
| Q2 24 | $-7.1M | — | ||
| Q1 24 | $-4.2M | — |
营业利润率BTMDDFTX
| Q4 25 | 14.7% | — | ||
| Q3 25 | 17.2% | — | ||
| Q2 25 | 22.0% | — | ||
| Q1 25 | 19.8% | — | ||
| Q4 24 | 5.6% | — | ||
| Q3 24 | 23.7% | — | ||
| Q2 24 | 12.7% | — | ||
| Q1 24 | 22.3% | — |
净利率BTMDDFTX
| Q4 25 | 4.2% | — | ||
| Q3 25 | 17.1% | — | ||
| Q2 25 | 6.5% | — | ||
| Q1 25 | 28.0% | — | ||
| Q4 24 | 7.4% | — | ||
| Q3 24 | 20.8% | — | ||
| Q2 24 | -14.4% | — | ||
| Q1 24 | -8.9% | — |
每股收益（稀释后）BTMDDFTX
| Q4 25 | $0.05 | — | ||
| Q3 25 | $0.22 | — | ||
| Q2 25 | $0.10 | — | ||
| Q1 25 | $0.37 | — | ||
| Q4 24 | $0.09 | — | ||
| Q3 24 | $0.33 | — | ||
| Q2 24 | $-0.21 | — | ||
| Q1 24 | $-0.12 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.1M | $99.7M |
| 总债务越低越好 | $103.1M | — |
| 股东权益账面价值 | $-58.5M | $78.1M |
| 总资产 | $107.6M | $124.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BTMDDFTX
| Q4 25 | $24.1M | — | ||
| Q3 25 | $28.0M | — | ||
| Q2 25 | $19.6M | — | ||
| Q1 25 | $41.7M | — | ||
| Q4 24 | $39.3M | — | ||
| Q3 24 | $38.2M | — | ||
| Q2 24 | $26.4M | — | ||
| Q1 24 | $78.8M | — |
总债务BTMDDFTX
| Q4 25 | $103.1M | — | ||
| Q3 25 | $104.7M | — | ||
| Q2 25 | $106.3M | — | ||
| Q1 25 | $107.8M | — | ||
| Q4 24 | $109.4M | — | ||
| Q3 24 | $110.9M | — | ||
| Q2 24 | $112.5M | — | ||
| Q1 24 | $114.1M | — |
股东权益BTMDDFTX
| Q4 25 | $-58.5M | — | ||
| Q3 25 | $-72.8M | — | ||
| Q2 25 | $-85.1M | — | ||
| Q1 25 | $-90.0M | — | ||
| Q4 24 | $-105.9M | — | ||
| Q3 24 | $-130.3M | — | ||
| Q2 24 | $-143.2M | — | ||
| Q1 24 | $-36.0M | — |
总资产BTMDDFTX
| Q4 25 | $107.6M | — | ||
| Q3 25 | $111.3M | — | ||
| Q2 25 | $104.8M | — | ||
| Q1 25 | $123.4M | — | ||
| Q4 24 | $122.4M | — | ||
| Q3 24 | $101.3M | — | ||
| Q2 24 | $92.9M | — | ||
| Q1 24 | $160.1M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.6M | $-20.6M |
| 自由现金流经营现金流 - 资本支出 | $6.5M | — |
| 自由现金流率自由现金流/营收 | 14.0% | — |
| 资本支出强度资本支出/营收 | 2.3% | — |
| 现金转化率经营现金流/净利润 | 3.87× | — |
| 过去12个月自由现金流最近4个季度 | $30.2M | — |
8季度趋势，按日历期对齐
经营现金流BTMDDFTX
| Q4 25 | $7.6M | — | ||
| Q3 25 | $14.1M | — | ||
| Q2 25 | $7.1M | — | ||
| Q1 25 | $6.5M | — | ||
| Q4 24 | $12.4M | — | ||
| Q3 24 | $15.6M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $7.4M | — |
自由现金流BTMDDFTX
| Q4 25 | $6.5M | — | ||
| Q3 25 | $13.6M | — | ||
| Q2 25 | $5.3M | — | ||
| Q1 25 | $4.8M | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $14.0M | — | ||
| Q2 24 | $7.4M | — | ||
| Q1 24 | $6.7M | — |
自由现金流率BTMDDFTX
| Q4 25 | 14.0% | — | ||
| Q3 25 | 28.3% | — | ||
| Q2 25 | 10.8% | — | ||
| Q1 25 | 9.9% | — | ||
| Q4 24 | 21.5% | — | ||
| Q3 24 | 27.3% | — | ||
| Q2 24 | 15.1% | — | ||
| Q1 24 | 14.2% | — |
资本支出强度BTMDDFTX
| Q4 25 | 2.3% | — | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 3.7% | — | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 1.5% | — |
现金转化率BTMDDFTX
| Q4 25 | 3.87× | — | ||
| Q3 25 | 1.72× | — | ||
| Q2 25 | 2.22× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 3.34× | — | ||
| Q3 24 | 1.45× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BTMD
| Product Revenue | $45.3M | 98% |
| Disposable Trocars Product Revenue | $1.2M | 3% |
DFTX
暂无分部数据
